Novartis Scemblix® demonstrates sustained response rate in
Updated 48-week data from Phase III ASCEMBL trial consistent with improved major molecular response (MMR) rate of Scemblix® (asciminib) vs. Bosulif®*...
Stay updated with breaking news from Durable Responses. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Updated 48-week data from Phase III ASCEMBL trial consistent with improved major molecular response (MMR) rate of Scemblix® (asciminib) vs. Bosulif®*...
/PRNewswire/ -- Novartis today announced new 48-week data from the Phase III ASCEMBL trial of Scemblix® (asciminib) demonstrating that the results observed in...
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral...
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral...
Investegate announcements from NOVARTIS AG CHF0.50(REGD), FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia